GO
Loading...

Enter multiple symbols separated by commas

Bristol-Myers Squibb Co

More

  • U.S. top court rejects hepatitis B drug patent case Monday, 4 May 2015 | 9:40 AM ET

    WASHINGTON, May 4- The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the...

  • Final Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 6:14 PM ET

    Baxter International Inc. fell$. 48 or. 7 percent, to $69.75. Bristol-Myers Squibb Co. fell$. 25 or. 4 percent, to $64.29. Eli Lilly& Co. rose $1.10 or 1.5 percent, to $72.28.

  • Midday Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 2:53 PM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $69.74. Bristol-Myers Squibb Co. fell$. 56 or. 9 percent, to $63.98. Eli Lilly& Co. rose$. 97 or 1.4 percent, to $72.15.

  • Early Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 10:45 AM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $69.92. Bristol-Myers Squibb Co. rose$. 19 or. 3 percent, to $64.73. Eli Lilly& Co. rose $1.00 or 1.4 percent, to $72.18.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Final Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 6:04 PM ET

    Baxter International Inc. fell$. 14 or. 2 percent, to $70.23. Bristol-Myers Squibb Co. fell$. 62 or 1.0 percent, to $64.54. Eli Lilly& Co. rose$. 29 or. 4 percent, to $71.18.

  • FDA approves generic versions of schizophrenia drug Tuesday, 28 Apr 2015 | 5:26 PM ET

    WASHINGTON— The Food and Drug Administration said Tuesday it has approved the first generic versions of Abilify, the blockbuster pill used to treat schizophrenia and bipolar disorder. The agency approved generic versions of the drug from four companies: Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd....

  • Pfizer Inc., Merck& Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their revenue from selling products overseas. Pfizer cut its 2015 earnings-per-share forecast by a nickel, to between $1.95 and $2.05, in the face of two fierce headwinds. New York- based Pfizer said those two factors will reduce 2015...

  • Midday Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 1:50 PM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $70.24. Bristol-Myers Squibb Co. fell$. 87 or 1.3 percent, to $64.29. Eli Lilly& Co. rose$. 29 or. 4 percent, to $71.18.

  • Early Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 10:39 AM ET

    Baxter International Inc. fell$. 48 or. 7 percent, to $69.89. Bristol-Myers Squibb Co. fell $1.39 or 2.1 percent, to $63.77. Eli Lilly& Co. fell$. 20 or. 3 percent, to $70.70.

  • April 28- Merck& Co's shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared with $1.71...

  • Bristol-Myers beats Street 1Q forecasts Tuesday, 28 Apr 2015 | 7:39 AM ET

    NEW YORK _ Bristol-Myers Squibb Co. on Tuesday reported first-quarter profit of $1.19 billion. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 50 cents per share. Seven analysts surveyed by Zacks expected $3.84 billion.

  • Cost-cutting and sales of new drugs helped Pfizer overcome a strong dollar and patent expirations to beat Wall Street projections for the first quarter, though it cut its outlook for the year, citing the unfavorable currency exchange rates. Most major drugmakers have overcome multibillion-dollar revenue hits from the unprecedented wave of patent...

  • Merck hurdles Wall Street forecasts Tuesday, 28 Apr 2015 | 7:18 AM ET

    Drugmaker Merck& Co. easily beat Wall Street expectations, sending its shares up sharply, despite first-quarter profit plunging 44 percent. While Merck's prescription drug sales jumped 16 percent in the U.S. in the quarter, they were down sharply in the huge Europe and Japan markets and some other regions. The world's fifth-biggest drugmaker said its net...

  • Final Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 6:06 PM ET

    Baxter International Inc. fell$. 77 or 1.1 percent, to $70.37. Bristol-Myers Squibb Co. fell$. 64 or 1.0 percent, to $65.16. Johnson& Johnson fell$. 50 or. 5 percent, to $100.58.

  • Midday Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 1:50 PM ET

    Baxter International Inc. fell$. 46 or. 6 percent, to $70.68. Bristol-Myers Squibb Co. fell$. 55 or. 8 percent, to $65.25. Eli Lilly& Co. fell$. 61 or. 9 percent, to $70.97.

  • Early Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 11:25 AM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $71.29. Bristol-Myers Squibb Co. rose$. 16 or. 2 percent, to $65.96. Eli Lilly& Co. rose$. 09 or. 1 percent, to $71.67.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • April 27- Drug developer Celladon Corp said it expected to announce lay-offs and cost cuts as its stock plunged to an all-time low after the company's lead experimental gene therapy to treat heart failure failed a key trial. Celladon lost nearly 80 percent of its market value in early trading on Monday, with the stock falling to a record low of $2.76.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...